---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-25-041807"
form_type: "8-K"
ticker: "GRCE"
cik: "0001444192"
company_name: "Grace Therapeutics, Inc."
filed_at: "2025-11-13T23:59:59+00:00"
generated_at: "2026-05-16T20:17:40.177860+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Grace Therapeutics reports Q2 loss of $0.9M; FDA accepts NDA for GTx-104 with PDUFA April 23, 2026

## Summary
- Net loss $0.9M ($0.06 loss per share) vs $3.4M ($0.30 loss) in Q2 last year.
- FDA accepted NDA for GTx-104 (nimodipine IV) for aSAH; PDUFA target date April 23, 2026.
- U.S. patent issued for IV dosing regimen; IP protection extended to 2043.
- Cash $16.9M at Sept 30, 2025; ~$20.0M at Oct 31, 2025 after $4.0M warrant exercises.
- R&D expenses fell 80% to $0.6M due to completion of Phase 3 STRIVE-ON trial.

## SEC filing metadata
- accession: 0001140361-25-041807
- form_type: 8-K
- ticker: GRCE
- cik: 0001444192
- company_name: Grace Therapeutics, Inc.
- filed_at: 2025-11-13T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1444192/000114036125041807/0001140361-25-041807-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1444192/000114036125041807/ef20058656_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-25-041807
- JSON: https://secwatch.observer/filing/0001140361-25-041807.json
- Plain text: https://secwatch.observer/filing/0001140361-25-041807.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.